¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"opioid antagonists"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® opioid ÇÑ±Û ¾ÆÆíÀ¯»çÁ¦
¼³¸í   
  1. ¾ÆÆíÁ¦Á¦¿Í °°Àº ÀÛ¿ëÀ» °¡Áø ÇÕ¼º¸¶¾àÀ¸·Î¼­ ¾ÆÆíÀ¯µµÃ¼°¡ ¾Æ´Ñ °Í. Á¾·ù·Î´Â heroin, meperidine, dihydromorphine(Dilaudid), methadone µîÀÌ ÀÖ´Ù. 2. ¼¼Æ÷¸·ÀÇ ¾ÆÆíÁ¦Á¦ ¼ö¿ëü¿Í »óÈ£ÀÛ¿ëÇÔÀ¸·Î½á ¾ÆÆíÁ¦Á¦¿Í °°Àº È¿°ú¸¦ ³ªÅ¸³»´Â Ãµ¿¬»ê ÆéƼµå.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • opioid
    ¾ÆÆíÀ¯»çÁ¦
  • opioid agonist
    ¾ÆÆíÀ¯»çÀÛ¿ëÁ¦
  • opioid analgesic
    ¾ÆÆíÀ¯»çÁøÅëÁ¦
  • opioid antagonist
    ¾ÆÆíÀ¯»çÁ¦´ëÇ×Á¦
  • opioid receptor
    ¾ÆÆíÀ¯»çÁ¦¼ö¿ëü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • opioid
    ¾ÆÆíÀ¯»çÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • opioid agonist
    ¾ÆÆíÀ¯»çÀÛ¿ëÁ¦
  • opioid analgesic
    ¾ÆÆíÀ¯»çÁøÅëÁ¦
  • opioid antagonist
    ¾ÆÆíÀ¯»ç¹°Áú´ëÇ×Á¦
  • opioid
    ¾ÆÆíÀ¯»çÁ¦
  • opioid receptor
    ¾ÆÆíÀ¯»ç¹°Áú¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • opioid
    ¾ÆÆíÀ¯»ç¾à¹°, ¾ÆÆí¾çÁ¦Á¦.
  • opioid
    ¾ÆÆí¾çÁ¦Á¦
  • opioid
    ¾ÆÆíÀ¯»ç¾à¹°, ¾ÆÆí¾çÁ¦Á¦.
  • opioid
    ¾ÆÆí(¾ç)Á¦Á¦
  • opioid
    ¾ÆÆíÀ¯»ç¾à¹°, ¾ÆÆí°èÁ¦Á¦.
  • opioid
    ¾ÆÆí¾çÁ¦Á¦(¾ÆÆíÁ¦¼ö¿ëü¿¡ ÀÛ¿ë,¾ÆÆíÁ¦¿Í
  • opioid abuse
  • opioid agonist
    ¾ÆÆí¾çÀÛ¿ëÁ¦
  • opioid analgesic
    ¾ÆÆí¾çÁøÅëÁ¦.
  • opioid analgesic
    ¾ÆÆíÀ¯»çÁøÅëÁ¦, ¾ÆÆí°èÁøÅëÁ¦.
  • opioid antagonist
    ¾ÆÆí¾ç±æÇ×Á¦
  • opioid dependence
    ¾ÆÆí¾çÁ¦Á¦ ÀÇÁ¸(ëýðí)
  • opioid intoxication
    ¾ÆÆí¾çÁ¦Á¦ Áßµ¶(ñéÔ¸)
  • opioid peptide
    ¾ÆÆí¾çÆéƼµå<ÆéŸÀ̵å>.
  • opioid peptide
    ¾ÆÆíÀ¯»çÆéƼµå<ÆéŸÀ̵å>.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • glutamine antagonists
    ±Û·çŸ¹Î ±æÇ×Á¦(ÑÏù÷ð¥)
  • opioid
    ¾ÆÆí°è(ͧ)¾à¹°(å·Úª)
  • opioid peptide
    ¾ÆÆí°è(ͧ) ÆéŸÀ̵å
  • opioid receptor
    ¾ÆÆí°è(ͧ) ¾à¹°¼ö¿ëü(å·Úªáôé»ô÷)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
POP diphosphate group; pain on palpation; paroxypropione; persistent occipitoposterior [fetal position];...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CCA Calcium channel antagonists
H(2)RA H(2) receptor antagonists
LTRA Leukotriene receptor antagonists
AIIRA angiotensin II receptor antagonists
OR 1-opioid receptor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dopaminergic antagonists
    µµÆÄ¹Î¼ºÀÇ ±æÇ×Á¦
  • opioid
    ¾ÆÆí À¯»ç ¾à¹°, ¾ÆÆí¾ç Á¦Á¦
    1. ¾ÆÆíÁ¦Á¦¿Í °°Àº ÀÛ¿ëÀ» °¡Áø ÇÕ¼º ¸¶¾àÀ¸·Î¼­ ¾ÆÆí À¯µµÃ¼°¡ ¾Æ´Ñ °Í. 2. ¼¼Æ÷¸·ÀÇ ¾ÆÆíÁ¦ ¼ö¿ëü¿Í »óÈ£ ÀÛ¿ëÇÔÀ¸·Î½á ¾ÆÆíÁ¦¿Í °°Àº È¿°ú¸¦ ³ªÅ¸³»´Â õ¿¬»ê ÆéƼµå.
  • opioid dependence
    ¾ÆÆí¾ç Á¦Á¦ ÀÇÁ¸
  • opioid peptide
    ¾ÆÆí¾ç ÆéƼµå, ¾ÆÆí¾ç ÆéŸÀ̵å
  • opioid-mediated analgesia system
    ¾ÆÆí ¸Å°³ ÁøÅë°è
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
opioid antagonists Agents such as naloxone and naltrexone which have high affinity for opiate receptors but do not activate these receptors. These drugs block the effects of exogenously administered opioids such as morphine, heroin, meperidine, and methadone, or of endogenously released endorphins and enkephalins.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
analgesics, opioid Narcotic or opioid substances, synthetic or semisynthetic agents producing profound analgesia, drowsiness, and changes in mood. Mood changes may be pleasurable, therefore creating a potential for the abuse of these agents; the prototype of these is morphine to which all other analgesics are compared.
(12 Dec 1998)
receptors, opioid Cell membrane proteins that bind opioids and trigger intracellular changes which influence the behaviour of cells. The endogenous ligands for opioid receptors in mammals include three families of peptides, the enkephalins, endorphins, and dynorphins. The receptor classes include mu, delta, and kappa receptors. Sigma receptors bind several psychoactive substances, including certain opioids, but their endogenous ligands are not known.
(12 Dec 1998)
receptors, opioid, delta A class of opioid receptors recognised by its pharmacological profile. Delta opioid receptors bind endorphins and enkephalins with approximately equal affinity and have less affinity for dynorphins.
(12 Dec 1998)
receptors, opioid, kappa A class of opioid receptors recognised by its pharmacological profile. Kappa opioid receptors bind dynorphins with a higher affinity than endorphins which are themselves preferred to enkephalins.
(12 Dec 1998)
receptors, opioid, mu A class of opioid receptors recognised by its pharmacological profile. Mu opioid receptors bind, in decreasing order of affinity, endorphins, dynorphins, met-enkephalin, and leu-enkephalin. They have also been shown to be molecular receptors for morphine.
(12 Dec 1998)
mixed opioid agonist-antagonist <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type.
(13 Nov 1997)
opioid Originally, a term denoting synthetic narcotics resembling opiates but increasingly used to refer to both opiates and synthetic narcotics.
(05 Mar 2000)
opioid agonist <pharmacology> Any morphine-like compound that produces bodily effects including pain relief, sedation, constipation and respiratory depression.
(16 Dec 1997)
opioid partial agonist <pharmacology> A compound that has an affinity for and stimulates physiologic activity at the same cell receptors as opioid agonists but that produces only a partial (i.e., submaximal) bodily response.
(16 Dec 1997)
opioid peptides The endogenous peptides with opiate-like activity. The three major classes currently recognised are the enkephalins, the dynorphins, and the endorphins. Each of these families derives from different precursors, proenkephalin, prodynorphin, and pro-opiomelanocortin, respectively. There are also at least three classes of opioid receptors, but the peptide families do not map to the receptors in a simple way.
(12 Dec 1998)
opioid receptor <pharmacology> A membrane protein, widely distributed in animal cells, but especially in the brain (enkephalin receptors) and gut. The natural ligands are the opiate peptide neurotransmitters, but the name is given because opiates are potent agonists that occupy the receptors and mimic the action of the natural transmitters.
(18 Nov 1997)
opioid-related disorders Disorders related or resulting from abuse or mis-use of opioids.
(12 Dec 1998)
adrenergic alpha-antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
(12 Dec 1998)
adrenergic antagonists Drugs that bind to but do not activate adrenergic receptors. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters epinephrine and norepinephrine.
(12 Dec 1998)
adrenergic beta-antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • opioid
    ¿ÀÇÇ¿ÀÀ̵å(¾ÆÆí ºñ½ÁÇÑ ÀÛ¿ëÀ» ÇÏ´Â ÇÕ¼º ÁøÅë,¸¶ÃëÁ¦)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á